Unicycive Therapeutics (UNCY) Operating Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Operating Expenses data on file, last reported at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 5.61% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (down 3.03% YoY), and the FY2025 full-year result was $29.5 million, down 8.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $8.4 million, up from $7.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $9.3 million in Q4 2024 and bottomed at $3.5 million in Q1 2022.
• The 5-year median for Operating Expenses is $6.5 million (2022), against an average of $6.5 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 383.86%; it then dropped 22.0% in 2025.
• A 5-year view of Operating Expenses shows it stood at $5.3 million in 2022, then increased by 18.55% to $6.3 million in 2023, then jumped by 46.7% to $9.3 million in 2024, then decreased by 22.0% to $7.2 million in 2025, then gained by 16.79% to $8.4 million in 2026.
• The last three Operating Expenses figures came in at $8.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.

Peer Comparison